Laboratory Corp. of America Holdings  

(Public, NYSE:LH)   Watch this stock  
Find more results for LH
174.39
+1.21 (0.70%)
Jan 19 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 173.22 - 174.79
52 week 128.00 - 174.79
Open 174.06
Vol / Avg. 637,507.00/531,335.00
Mkt cap 17.86B
P/E 24.34
Div/yield     -
EPS 7.17
Shares 102.10M
Beta 0.87
Inst. own 96%
Feb 27, 2018
Laboratory Corporation of America Holdings Investor & Analyst Day Add to calendar
Feb 6, 2018
Q4 2017 Laboratory Corporation of America Holdings Earnings Release - 9:30AM EST - Add to calendar
Feb 6, 2018
Q4 2017 Laboratory Corporation of America Holdings Earnings Call - 9:00AM EST - Add to calendar
Jan 9, 2018
Laboratory Corporation of America Holdings at JPMorgan Healthcare Q&A Session Conference
Jan 9, 2018
Laboratory Corporation of America Holdings at JPMorgan Healthcare Conference - Webcast
Nov 7, 2017
Laboratory Corporation of America Holdings at Credit Suisse Healthcare Conference - Webcast
Oct 25, 2017
Q3 2017 Laboratory Corporation of America Holdings Earnings Release
Oct 25, 2017
Q3 2017 Laboratory Corporation of America Holdings Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 6.91% 7.60%
Operating margin 12.85% 13.61%
EBITD margin - 19.39%
Return on average assets 4.66% 5.17%
Return on average equity 12.07% 14.01%
Employees 52,000 -
CDP Score - -

Address

358 S MAIN ST
BURLINGTON, NC 27215-5837
United States - Map
+1-336-2291127 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). The LCD segment is an independent clinical laboratory business, which offers menu of frequently requested and specialty testing through an integrated network of primary and specialty laboratories across the United States. The CDD segment offers drug development services, and provides a range of drug research and development (R&D) and market access services to biopharmaceutical companies and medical device companies across the world. It serves a range of customers, including managed care organizations (MCOs), biopharmaceutical companies, governmental agencies, physicians and other healthcare providers.

Officers and directors

David P. King Chairman of the Board, President, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Glenn A. Eisenberg Chief Financial Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
John D. Ratliff Chief Executive Officer - Covance Drug Development
Age: 57
Bio & Compensation  - Reuters
Lisa J. Uthgenannt Chief Human Resource Officer
Age: 56
Bio & Compensation  - Reuters
Edward T. Dodson Senior Vice President, Chief Accounting Officer, Principal Accounting Officer
Age: 63
Bio & Compensation  - Reuters
Lance V. Berberian Senior Vice President, Chief Information Officer
Age: 54
Bio & Compensation  - Reuters
F. Samuel Eberts III Senior Vice President, Chief Compliance Officer, Secretary, Chief Legal Officer
Age: 57
Bio & Compensation  - Reuters
Robert E. Mittelstaedt Jr. Lead Independent Director
Age: 73
Bio & Compensation  - Reuters
Kerrii B. Anderson Independent Director
Age: 60
Bio & Compensation  - Reuters
Jean-Luc Belingard Independent Director
Age: 68
Bio & Compensation  - Reuters